U.S. Medical Equipment Stock News

NYSE:JELD
NYSE:JELDBuilding

JELD-WEN (JELD) Is Down 41.0% After Job Cuts, Losses, and European Business Review—Has the Bull Case Changed?

JELD-WEN Holding, Inc. recently reported third-quarter 2025 results revealing a drop in sales to US$809.5 million and a net loss of US$367.6 million, alongside plans to cut approximately 850 jobs, goodwill impairment charges of US$196.9 million, and a lowered full-year revenue outlook. The company also announced a review of strategic alternatives for its European business, which accounted for roughly US$1.1 billion in 2024 revenue, highlighting a significant reevaluation of its global...
NasdaqCM:ARAY
NasdaqCM:ARAYMedical Equipment

Accuray (ARAY) Losses Increase 28.3% Annually, Challenging Turnaround Narrative Despite Profitability Forecast

Accuray (ARAY) has remained unprofitable, with losses deepening at an annual rate of 28.3% over the past five years. While revenue is projected to grow at 4.4% per year, which is slower than the broader US market’s 10.4% average, earnings are expected to rise sharply at 116.63% per year. This sets the company on course to become profitable within three years. With a Price-To-Sales Ratio of 0.3x and the current share price trading below the estimated fair value of $5.17, investors are keeping...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Ocugen (OCGN): Valuation Pressures Challenge Bullish Narrative as Profitability Remains Elusive

Ocugen (OCGN) is projected to deliver rapid revenue growth of 75.3% per year, with earnings expected to rise 77.45% annually, both far exceeding the broader US market estimates. The company remains unprofitable, having posted a 3.8% average annual increase in losses over the past five years, and its share price currently trades at $1.38. Investors will weigh these aggressive growth forecasts against Ocugen’s continued net margin struggles and premium valuation, especially given a...
NYSE:DFH
NYSE:DFHConsumer Durables

Has the Recent 24% Drop Created an Opportunity in Dream Finders Homes for 2025?

Wondering whether Dream Finders Homes is a hidden bargain, an overpriced risk, or something in between? You are not alone. Today's market moves have many investors asking the same question. The stock has taken a wild ride recently, dropping 10.6% in the last week and down 24.6% over the past month, with year-to-date returns at -15.7%. Looking further back, shares are still up an impressive 92.9% over the last three years, even after a tough 12 months marked by a -38.9% decline. Much of this...
NasdaqGS:HNST
NasdaqGS:HNSTPersonal Products

Honest Company Stock Sinks 51% as New Product Launches Spark Valuation Debate

Wondering if Honest Company stock is a smart buy at this price? Let’s dive into what recent numbers and real trends are telling us about its true value. The stock has seen a notable drop lately, falling 16.9% over the past month and 51.4% year-to-date. This has sparked new questions about its growth outlook and the risks investors may be seeing. Recent headlines suggest Honest Company is exploring new product launches and expanding its retail partnerships. These moves could reshape its...
NYSE:OPFI
NYSE:OPFIConsumer Finance

A Fresh Look at OppFi (OPFI) Valuation After Raised Revenue Guidance and Buyback Completion

OppFi (OPFI) just raised its revenue expectations for 2025 and completed a notable share repurchase. These are two clear signals that management is confident about the company’s direction and prospects next year. See our latest analysis for OppFi. After the upbeat revenue outlook and completion of its buyback, OppFi’s positive momentum stands out. The 1-year total shareholder return sits at 89.5%, and its 3-year total return is an impressive 454%. These strong numbers have caught investor...